Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Net Margin (2021 - 2025)

Kiniksa Pharmaceuticals International's Net Margin history spans 5 years, with the latest figure at 35.57% for Q4 2025.

  • For Q4 2025, Net Margin fell 5819.0% year-over-year to 35.57%; the TTM value through Dec 2025 reached 4.0%, down 244.0%, while the annual FY2025 figure was 4.0%, 244.0% down from the prior year.
  • Net Margin reached 35.57% in Q4 2025 per KNSA's latest filing, down from 10.19% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 682.59% in Q4 2021 to a low of 539.5% in Q2 2021.
  • Average Net Margin over 5 years is 6.41%, with a median of 3.6% recorded in 2024.
  • The largest YoY upside for Net Margin was 47858bps in 2022 against a maximum downside of -61720bps in 2022.
  • A 5-year view of Net Margin shows it stood at 682.59% in 2021, then plummeted by -90bps to 65.39% in 2022, then surged by 113bps to 139.54% in 2023, then plummeted by -84bps to 22.62% in 2024, then tumbled by -257bps to 35.57% in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Net Margin are 35.57% (Q4 2025), 10.19% (Q3 2025), and 11.37% (Q2 2025).